Compare CERT & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CERT | EVMN |
|---|---|---|
| Founded | 2008 | 2020 |
| Country | United States | United States |
| Employees | N/A | 48 |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 860.9M | 825.5M |
| IPO Year | 2020 | N/A |
| Metric | CERT | EVMN |
|---|---|---|
| Price | $5.24 | $22.67 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 10 | 10 |
| Target Price | $11.67 | ★ $43.88 |
| AVG Volume (30 Days) | ★ 3.2M | 341.8K |
| Earning Date | 05-11-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 87.50 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $418,838,000.00 | N/A |
| Revenue This Year | $4.18 | N/A |
| Revenue Next Year | $5.39 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 8.75 | N/A |
| 52 Week Low | $4.45 | $13.89 |
| 52 Week High | $13.88 | $33.20 |
| Indicator | CERT | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 44.91 | 45.97 |
| Support Level | $5.19 | $21.39 |
| Resistance Level | $6.47 | $23.08 |
| Average True Range (ATR) | 0.35 | 1.43 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 39.65 | 45.87 |
Certara Inc accelerates medicines to patients using biosimulation software and technology to transform traditional drug discovery and development. It provides modeling and simulation, regulatory science, and assessment software and services to help clients reduce clinical trials, accelerate regulatory approval, and increase patient access to medicines. The company has its business presence in the Americas, which is also its key revenue-generating market, EMEA, and the Asia Pacific region.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.